Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 29CNS 1Breast 1

Conditions

Breast Neoplasms 20Triple Negative Breast Neoplasms 14Ovarian Neoplasms 7Melanoma 7Carcinoma, Non-Small-Cell Lung 6Neoplasms 5Neoplasm Metastasis 5Carcinoma, Renal Cell 5Stomach Neoplasms 4Pancreatic Neoplasms 4Head and Neck Neoplasms 4Carcinoma, Transitional Cell 4Uterine Cervical Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Small Cell Lung Carcinoma 3Sarcoma 3Endometrial Neoplasms 3Carcinoma, Hepatocellular 3Prostatic Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Multiple Myeloma 2Mesothelioma 2Lymphoma, Non-Hodgkin 2Lymphoma 2Lung Neoplasms 2Liver Neoplasms 2Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 2Leukemia, Myeloid, Acute 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Leukemia, Lymphocytic, Chronic, B-Cell 2

Interventions

Nivolumab 2Cyclophosphamide 2tislelizumab 1spartalizumab 1pembrolizumab 1montanide ISA 51 1glembatumumab vedotin 1fludarabine phosphate 1entinostat 1cemiplimab 1Toll-Like Receptor 1 1Surveys and Questionnaires 1Specimen Handling 1Rose Bengal 1Magnetic Resonance Spectroscopy 1Ipilimumab 1Interleukin-2 1Interleukin-13 1Focus Groups 1Fluorodeoxyglucose F18 1Cryosurgery 1CTLA-4 Antigen 1CR011-vcMMAE 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Uveal Melanoma × Ipilimumab × Breast × Clear all
NCT03326258 2018-07-18

Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 1/2 Withdrawn
BreastDermatologic

Uveal Melanoma, Breast Neoplasms, Melanoma, Neoplasm Metastasis, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡